Rodabe N. Amaria, MD, explains a trial of OBX-115, a novel engineered tumor infiltrating lymphocyte therapy, in checkpoint ...

PG medical pre-clinical courses in Karnataka face low enrollment due to lack of job prospects, prompting fee waivers and job ...

Tumor inflitrating lymphocyte therapies are a promising type of cellular immunotherapy used to treat a broad range of solid malignant tumors.

SYN-2510 shows early clinical promise in solid tumors, with plans for phase 3 trials in NSCLC and breast cancer by mid-to-late 2026. Despite having cash to fund operations until 2026, TIL's ...

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You accept for the main domain ...

The Exosome Therapeutics Market is projected to grow from $30 million in 2029 to $1.4 billion by 2040, at a CAGR of 41.1%.

The Department of Pharmaceuticals, Government of India, organised an Industry dialogue on the Promotion of Research and ...

Higher tumor-infiltrating lymphocyte (TIL) levels were independently associated ... “This updated analysis of the ShortHER randomized clinical trial is, to our knowledge, the first report ...

With the dynamic and changing landscape of healthcare, patient safety is at the top of the list of priorities in the pharmaceutical world. More complex drugs pose greater complications in tracking and ...

Excellence Award This award recognises individuals who have made significant contributions to NUHS's clinical, research and education missions. Their work has had a major impact, leading to improved ...

Navigate life's highs and lows with reason and logic to achieve happiness, as explained by Kaushik Basu in his book.

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue. Click to read why ABBV is a Hold.